echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > TCR Therapeutics was recognized by the FDA as a breakthrough therapy and is expected to file a regulatory application in the third quarter

    TCR Therapeutics was recognized by the FDA as a breakthrough therapy and is expected to file a regulatory application in the third quarter

    • Last Update: 2021-02-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Tebentafusp innovatively combines TCR targeting tumor antigens with immune-effect domains that bind to CD3 subjects.
    designed to guide and activate T-cells, allowing them to identify and kill cancer cells.
    Tebentafusp specific target gp100, an antigen expressed in melanin cells and melanoma.
    noteworthy is that the company's technology allows TCR to identify cancer antigens in cells with high affinity, which is expected to break through the limitations of existing antibody drugs and increase the number of identifiable targets from 10 percent to 90 percent.
    In addition, based on existing mechanisms for T-cell immersion of human tumors, Immunocore also points out that its TCR technology is expected to be used to treat immunologically "cold tumors", tumors with low mutation rates that have traditionally been difficult to attract the attention of the immune system.
    breakthrough therapy is based on phase 3 clinical trial results published in November 2020.
    -term analysis showed that tebentafusp showed significant survival benefits in treating patients with primary metastasis melanoma compared to other therapies chosen by the researchers, including dacarbazine, ipilimumab, or pembrolizumab.
    although the data are not yet fully mature, the tebentafusp group currently has a one-year survival rate of 73%, better than the other treatment groups of 58%.
    : This article is intended to introduce medical and health research, not treatment options recommended.
    if you need guidance on treatment options, visit a regular hospital.
    resources: s tebentafusp granted ByRessInse reserved The Therapy Designation for unresectable or metastatic uveal melanoma from FDA. Retrieved February 19, 2021, from [2] Bertil E. Damato et al., (2019), Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma, Cancers, DOI:
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.